Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Melanie L Munguia"'
Autor:
Ximin Chen, Giulia Parisi, Jiajia Cui, Orit Foord, Jim Johnston, Michael R Weist, Ethan BenDavid, Melanie L Munguia, Jessica Reyes
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 2 (2023)
Externí odkaz:
https://doaj.org/article/3b14c416e59546ee8c757bb37a0a227d
Autor:
Talar Tokatlian, Jiajia Cui, Michelle Kreke, Breanna DiAndreth, Emily D. Lim, Grace E. Asuelime, Jee-Young Mock, Kiran Deshmukh, Mark E. Daris, Alexander Kamb, Agi Hamburger, Melanie L. Munguia
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Cell therapy, with all its promise as a powerful solid-tumor modality, is still hampered by the fundamental obstacle of cancer therapy: the acute shortage of truly tumor-specific targets. It is well known that an average tumor contains los
Autor:
Talar Tokatlian, Jiajia Cui, Emily D. Lim, Agnes E. Hamburger, Breanna DiAndreth, Kiran Deshmukh, Melanie L. Munguia, Jee-Young Mock, Mark E. Daris, Michelle Kreke, Alexander Kamb, Grace E. Asuelime
Publikováno v:
Molecular immunology. 128
We describe an approach to cancer therapy based on exploitation of common losses of genetic material in tumor cells (loss of heterozygosity) (Basilion et al., 1999; Beroukhim et al., 2010). This therapeutic concept addresses the fundamental problem o
Autor:
Jaspal Singh Kang, Abby Lin, Julyun Oh, Alexander Kamb, Craig Pigott, Falene Chai, Michael Gallo, Melanie L. Munguia, Mikayel Mkrtichyan, Dora Toledo Warshaviak
Publikováno v:
Scientific Reports
Scientific Reports, Vol 9, Iss 1, Pp 1-12 (2019)
Scientific Reports, Vol 9, Iss 1, Pp 1-12 (2019)
Cell therapy using T cell receptors (TCRs) and chimeric antigen receptors (CARs) represents a new wave of immunotherapies garnering considerable attention and investment. Further progress in this area of medicine depends in part on improving the func
Autor:
Alexander Kamb, David G. Maloney, Jee-Young Mock, Grace E. Asuelime, Michelle Kreke, Kiran Deshmukh, Breanna DiAndreth, Agnes E. Hamburger, Melanie L. Munguia, William Y. Go, Talar Tokatlian, Mark E. Daris, Emily D. Lim
Publikováno v:
Blood. 136:23-24
Background: Chimeric Antigen Receptor (CAR) T-cell therapy is a proven, powerful clinical modality. However, it is still limited by the fundamental obstacle of cancer therapy: discriminating cancer from normal cells. Current FDA-approved CAR T-cell t